Recommendations regarding Mycobacterium tuberculosis
Tuberculosis is uncommon among HCT recipients. The main risk factor involves undergoing transplant in a country with a high endemic rate of TB. 450, 451 In countries in which TB is uncommon, TB is more prevalent among patients who have come to undergo HCT from countries or were born in countries with a higher rate of endemic TB. 452, 453 Patients with household members at risk (for example, recent immigrants, correctional facility discharges) also deserve particular attention. It must always be remembered that there is no definitive test to exclude TB and a high level of clinical awareness must be maintained in all immunosuppressed patients.
The rate of TB reported after HCT is 10 times less than that after solid organ transplantation, 454 as HCT patients do not receive lifelong immunosuppression. However, patients with prolonged immunosuppression, such as those with chronic GVHD, remain at risk for TB. As control of TB is T-cell mediated, restoration of T-cell function over time and with cessation of immunosuppression reduces the patient's risk of TB.
Most patients who developed TB after HCT did not have clearly identified risk factors. 455, 456 Most had normal pretransplant chest radiographs and no direct history of contact with TB. Most had been transplanted for leukemia, had received TBI-based conditioning and were allograft recipients. Most were receiving treatment for GVHD and were more than a 100 days after transplant.
Although most cases of TB occurred in allogeneic HCT recipients, 20% occurred in autologous recipients. Despite this low rate, 454 ,457 diagnostic vigilance must be maintained. For example, mycobacterial infection may occur more frequently in patients who underwent autologous HCT for chronic lymphocytic leukemia, in whom previous therapy with fludarabine and alemtuzumab induced profound T-cell deficiency and susceptibility to a variety of opportunistic infections. 458 Preventing exposure Hematopoietic cell transplant candidates and recipients should avoid exposure to persons or environments in which there is a substantial risk of respiratory contact with individuals with active TB. It is prudent to advise HCT candidates and recipients that certain occupations (for example, volunteer work or employment in health-care facilities, correctional institutions or shelters for the homeless) can increase their risk for TB exposure (BIII). 459 Preventing disease Evaluation of patients before HCT. Experts recommend evaluation for latent or active TB in patients who are candidates for HCT (BII). Assessment should include a history of the following:
Previous active TB Previous exposure-evaluated as high-priority contacts as per Centers For Disease Control (CDC) guidelines.
460
Results of previous tuberculin skin tests (TSTs) or IFN-g release assays (IGRA).
Experts disagree with regard to the convenience or benefit of routinely obtaining a TST or IGRA in every transplant candidate. Interpretation of TST may also be complicated by a history of earlier Bacillus CalmetteGua´rin (BCG) vaccination, although tuberculin reactivity after BCG tends to wane over time. 461 The American Thoracic Society states that a positive TST may be considered diagnostic of latent M. tuberculosis infection in BCG recipients who are at risk for recent M. tuberculosis infection or who have a medical condition that increases the risk of progression to active TB (CIII). 462 Owing to earlier chemotherapy-induced immunosuppression, TST is not as sensitive in HCT candidates as it is in the healthy population. IGRAs are specific for TB, but a negative test does not exclude latent TB infection, particularly in an immunocompromised patient. In a meta-analysis, IGRAs were found to be more sensitive than TSTs in immunocompromised patients suspected of having TB. 463 This was particularly the case among patients with autoimmune disease and among those receiving anti-TNF therapy (for example, infliximab), who are at particular risk for TB. 464 Studies specifically in HCT patients are awaited. However, Canada and the United States have made recommendations for the use of IGRAs in immunocompromised patients. 465, 466 Any patient with a recently positive TST or IGRA, or with a history of a positive test and no earlier preventive therapy, should be evaluated for active TB. At a minimum, the patient should be asked about symptoms of systemic disease, as well as about respiratory symptoms such as cough and shortness of breath, and a chest radiograph should be assessed (AII). 462 If active TB is detected, therapy and appropriate isolation should be initiated. HCT should be delayed until active infection is deemed controlled on the basis of clinical judgment, as no objective definition of adequate control has been formulated. If the TST or IGRA is positive but no active TB is identified, treatment for latent TB infection (Appendix 1) should be initiated, but HCT need not be delayed.
Indications for treatment of latent TB infection or prophylaxis
Owing to high risk of reactivation or new infection, prophylaxis should be administered to immunocompromised HCT recipients or candidates who have been exposed to someone with active, infectious (that is, sputum-smear positive) pulmonary or laryngeal TB, regardless of the HCT recipient's or candidate's TST or IGRA status (BIII); have a positive TST result-regardless of earlier BCG vaccination-without previous treatment and no evidence of active TB disease (BII). A positive TST with a history of BCG vaccination is still considered by the American Thoracic Society as an indication of prophylaxis in patients who 'have medical conditions that increase the risk for disease', 462 which presumably include HCT (CIII); have a positive IGRA result, without previous treatment and no evidence of active TB (BII).
A report of a high frequency of reactivation of previously treated TB after transplantation, especially in some parts of the world wherein the endemic prevalence of TB is high, suggests that such patients may be at high risk, and, therefore, INH prophylaxis should be considered (CIII).
467
The value of prophylaxis in countries with a high rate of TB, or in HCT patients from such countries, should be considered at an institutional level. Owing to the high prevalence of multidrug-resistant TB in some of these countries, single-agent prophylaxis may be ineffective. Consequently, maintaining a very high index of suspicion and providing early intervention may be preferable to universal prophylaxis. An HCT candidate or recipient who has been exposed to an active case of extrapulmonary, and therefore noninfectious, TB does not require preventive therapy (DIII).
Prophylactic regimens
Isoniazid (INH) is well tolerated after HCT, even with concurrent fluconazole use. 450, 467, 468 Concurrent use with itraconazole is not recommended, and the impact of voriconazole or posaconazole is not known. INH with pyridoxine should be continued for at least 9 months and until immunosuppression dosages are substantially reduced (that is, prednisolone o0.5 mg/kg in children or o20 mg daily in adults) (Appendix 1). INH can be started at the completion of conditioning therapy, or before conditioning if feasible, or if the clinical situation puts the patient at a higher risk of infection. Rifampin administered for 4 months is effective, but the potential for substantial drugdrug interactions between rifampin and immunosuppressive and other agents generally makes this option impractical. The combination of pyrazinamide and rifampin has been known to cause significant liver toxicity, and its use after HCT is not recommended (EII).
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Vaccination Bacillus Calmette-Gua´rin vaccination is contraindicated in HCT candidates (EII). Disseminated BCG infection has been reported among immunocompromised persons receiving BCG.
470
Donor evaluation Donors who live in or originate from countries in which TB is endemic have an increased risk of TB or latent TB, similar to the rest of the population. There is no known risk from transplanting hematopoietic progenitor cells from an untreated donor with latent or active TB. However, it would be prudent for prospective donors with active TB to defer donation until TB is well controlled, as determined by the donor's primary physician (EIII).
Recommendations regarding PCP
Preventing exposure Most cases of PCP were traditionally thought to occur from the reactivation of latent infection. However, suggestive animal data and well-documented human cases indicate that clinical disease can result from recent infection. Moreover, previously infected patients can be reinfected with new strains of Pneumocystis.
471-476 These observations and some intriguing clusters of PCP cases have suggested that person-to-person transmission is possible. [477] [478] [479] [480] Neither CDC nor most hospitals mandate respiratory precautions with regard to patients with PCP. However, many clinicians consider it logical that HCT recipients should avoid exposure to patients with PCP (CIII). There are no data-based guidelines with regard to how long such PCP patients should be isolated.
Preventing disease and disease recurrence Allogeneic SCT recipients. P. jiroveci pneumonia is a generally preventable complication of HCT. Programs must have vigorous systems to assure that PCP prophylaxis is prescribed by providers and adhered to by patients (AII). PCP prophylaxis is usually prescribed for allogeneic recipients from engraftment until at least 6 months after HCT (AII).
481 Some health-care providers initiate PCP prophylaxis before transplantation, depending on the underlying disease and the pretransplant conditioning regimens or previous chemotherapy (CII). Prophylaxis should be continued for longer than 6 months in patients who continue to receive immunosuppressive drugs (AII).
481-484
The preferred regimen for PCP prophylaxis is trimethoprim-sulfamethoxazole (TMP-SMX), because of its superior efficacy compared with aerosolized pentamidine, oral dapsone or oral atovaquone (AII).
485,486 TMP-SMX also provides some protection against other pathogens, including Toxoplasma, Nocardia, enteric pathogens, Plasmodium species, urinary pathogens and some respiratory pathogens. Although dapsone and atovaquone probably provide some protection against Toxoplasma, the broader spectrum of activity of TMP-SMX is among the reasons this drug is preferred.
Trimethoprim-sulfamethoxazole can delay engraftment and thus is not usually administered before engraftment occurs. TMP-SMX is variably tolerated, and toxicities include myelosuppression, hypersensitivity, hyperkalemia, nephritis, hepatitis and pancreatitis. The optimal dosage has not been defined in HCT patients. Many HCT programs use once-or twice-daily regimens (single-strength or double-strength tablets) 2-7 days per week (CIII), all of which seem efficacious.
There are no properly powered trials on which to base a recommendation for alternative regimens. Oral dapsone, 487 Oral dapsone is convenient, but a substantial number of patients allergic to TMP-SMX will also be intolerant of dapsone. Therefore, this drug is not recommended in patients who have had life-threatening reactions to TMP-SMX. Adverse reactions to dapsone include hypersensitivity, hemolysis (especially in patients with glucose-6-phosphate dehydrogenase deficiency), hepatitis and methemoglobinemia. Patients with glucose-6-phosphate dehydrogenase deficiency should not receive this drug. 488 Aerosolized pentamidine is well tolerated, with bronchospasm as the only common adverse effect, but may be less effective than other regimens. 494 Atovaquone is expensive but well tolerated; however, it is not well absorbed unless ingested with fatty foods. Thus, atovaquone might not be an optimal choice in patients with gut GVHD.
Recurrence of PCP in HCT recipients is rare. Nevertheless, patients recovering from PCP should continue on chemoprophylaxis until their immunosuppression is resolved (AII), although there are no clear parameters for defining this end point.
Autologous SCT recipients. P. jiroveci pneumonia develops in some autologous HCT recipients, although the rate is much lower than that among allogeneic recipients. PCP prophylaxis should be considered for autologous HCT recipients whose immunosuppression is substantial, either from an underlying condition or its treatment. Such patients include those with underlying lymphoma, leukemia or myeloma, especially when intensive treatment or conditioning regimens have included purine analogs (fludarabine, cladribine (2CdA)) or high-dose corticosteroids (BIII).
480,488 Duration of PCP prophylaxis in this setting has not been evaluated, but common practice is to extend prophylaxis 3-6 months after transplantation (CIII). For patients with ongoing immunomodulatory therapy after transplantation, a longer duration of prophylaxis may be necessary.
Recommendations regarding Toxoplasma gondii

Preventing exposure
In immunocompetent hosts, the initial acquisition of Toxoplasma most often occurs through exposure to cat feces or undercooked meat. All HCT recipients should be provided information regarding strategies to reduce their risk of exposure to Toxoplasma species (see Strategies for Safe Living). Although an unusual source of toxoplasmosis after HCT, potential donors for allogeneic HCT could be tested for IgG Abs to T. gondii Abs, 495 because T. gondii is reported to be transmitted by leukocyte transfusion 496 and HCT 497 (CIII).
be tested for IgG Ab to determine whether they are at risk for disease reactivation after HCT (BIII). 495 However, toxoplasmosis occurred in a limited number of HCT patients who were seronegative for T. gondii before transplant.
498 Most cases observed after allogeneic HCT occurred between 3 and 26 weeks after transplant, 499-501 but later occurrence was also reported in patients receiving long-term immunosuppression. The incidence of T. gondii disease varies according to the seroprevalence in the geographical area. Clinical reactivation occurs among 2-6% of those who are seropositive before HCT.
495,500-502 Cord blood transplant recipients may be at higher risk than other HCT recipients.
500
In allogeneic recipients who are seropositive for toxoplasmosis, the risk of reactivation varies with the kind of transplant and degree of immunosuppression. In a prospective study from Spain, weekly screening with quantitative PCR testing of blood in allogeneic seropositive HCT recipients over the first 6 months after transplant has shown that reactivation occurred in 16% (8-21%) of seropositive allogeneic HCT recipients.
500 Nucleic-acid-based reactivation typically precedes clinical symptoms by 4-16 days.
98,500
To facilitate the early identification of reactivated infection, PCR screening can be considered in patients at high risk (that is, patients who were seropositive before transplant and who received a cord blood graft, have developed GVHD and require immunosuppressive treatment, or who are not receiving TMP-SMX) (BII). PCR should preferably be performed in a reference laboratory by a quantitative method, using strict measures to reduce the risk of false-positive results (due to contamination) and false-negative results (due to the presence of inhibitors) (BIII). 503 Brain magnetic resonance imaging or computed tomography scans in HCT patients with toxoplasmosis may not show the characteristic ring-enhancing lesions of this disease; 504 therefore, a diagnostic workup (for example, PCR testing of cerebrospinal fluid or bronchoalveolar lavage samples and/or blood) should be initiated in patients with brain or pulmonary lesions who are seropositive for Toxoplasma (CIII).
T. gondii reactivation and disease are both rare, but have been reported in patients receiving TMP-SMX for P. jiroveci prophylaxis. 500, 505 In high-risk patients who are intolerant to TMP-SMX, a specific strategy for T. gondii should be implemented, because other P. jiroveci prophylactic drugs either do not penetrate the body site of reactivation (for example, aerosolized pentamidine) or their prophylactic efficacy after HCT is unknown (for example, dapsone, atovaquone). Such patients can either be treated prophylactically with one or more drugs effective against T. gondii (for example, clindamycin, pyrimethamine plus leucovorin, pyrimethamine plus sulfadiazine, or pyrimethamine and sulfadoxine plus leucovorin 506 ) or be monitored with PCR testing and given preemptive treatment (Appendix 1) (CIII).
506 There are no published prospective studies on the benefit-risk ratio of such strategies.
After therapy for toxoplasmosis, HCT recipients should continue receiving suppressive doses of TMP-SMX or an alternative regimen for the duration of their immunosuppression (BIII) (Appendix 1).
Other recommendations
Except for rare patients with pretransplant toxoplasmic chorioretinitis, who may benefit from secondary prophylaxis, 507 recipients of autologous transplants are at negligible risk for toxoplasmosis reactivation. No prophylaxis or screening for toxoplasmosis infection is recommended for autologous transplant recipients (CIII). Indications for toxoplasmosis prophylaxis are similar in children and adults, but children should receive pediatric doses (Appendix 1).
Recommendations regarding Nocardia infection
Preventing exposure All HCT recipients should be provided information on ways to reduce risks of exposure to Nocardia spp. Specific information should include the ubiquitous nature of this Gram-positive, weakly acid-fast aerobic actinomycete. Nocardia spp. are found primarily in dirt and stagnant water. Patients should be advised to avoid gardening, soil and plants while receiving immunosuppressive therapy (CIII). As infection occurs through inhalation, patients who wish to continue gardening may minimize exposure by wearing protective gear such as an N-95 mask and gloves (CIII).
Preventing disease and disease recurrence
The incidence of Nocardia infections is increased in patients with HCT compared with the general population (128 cases per 10 5 person per year vs 0.3-0.4 cases per 10 5 person per year). [508] [509] [510] The median time to onset is E200 days after transplant. 508, 510 Risk factors for disease include immunosuppression, corticosteroid use, neutropenia, active GVHD and concomitant opportunistic infections, especially CMV. [510] [511] [512] One study suggested that there may be decreased risk of infection in patients receiving TMP/SMX prophylaxis (CIII).
508 Notably, between 40 and 60% of cases in HCT patients occurred while the patient was receiving TMP/ SMX for PCP prophylaxis. 510, 512 Interestingly, most of these breakthrough cases were successfully treated with high-dose TMP/SMX. However, therapy for Nocardia infection should be chosen on the basis of appropriate identification of the Nocardia isolate and, if available, susceptibility testing, as other treatment options are possible.
Recommendations regarding Strongyloides stercoralis
Preventing exposure Allogeneic HCT recipients should avoid contact with outhouses and cutaneous exposure to soil or other surfaces that might be contaminated with human feces (AIII).
513
Allogeneic HCT recipients who work in settings in which they could be exposed to fecal matter (for example, hospitals or institutions) should wear gloves while working with patients or in areas with potential fecal contamination (AIII).
Preventing disease and disease recurrence
Histories should be obtained for all patients before HCT to identify potential exposure to Strongyloides through travel or residence in high-risk areas (that is, moist temperate areas such as the tropics, subtropics or the southeastern United States and Europe) (BIII). 513 HCT candidates who have unexplained peripheral eosinophilia or who have resided in or traveled to areas endemic for strongyloidiasis, even during the distant past, should be screened for asymptomatic strongyloidiasis before HCT (BIII). Options available for screening include stool examination and serological testing with an ELISA 514 or with an indirect immunofluorescence Ab test. 515 Generally, ELISA is the preferred screening method, but its sensitivity may be relatively low (o70%) in some immunocompromised patients (BIII). 516 Although stool examinations for strongyloidiasis are specific, the sensitivity achieved with X3 stool examinations is 60-70%; the sensitivity achieved with concentrated stool exams is, at best, 80%.
513 A total of X3 stool examinations should be performed if serological tests are unavailable or if strongyloidiasis is clinically suspected in a seronegative patient (BIII).
Hematopoietic cell transplant candidates with pretransplant screening tests positive for Strongyloides species or those with an unexplained eosinophilia and a travel or residence history indicating exposure to Strongyloides stercoralis should receive empirical treatment before transplantation, preferably with ivermectin (Appendix 1) (BIII).
517
There is no evidence supporting universal preemptive treatment, but given ivermectin's favorable safety profile and low cost, some clinicians advocate preemptive treatment for patients from endemic areas who have no symptoms, no eosinophilia and negative screening test results (CIII).
To prevent recurrence among HCT candidates, parasite clearance after therapy should be verified with X3 consecutive negative stool examinations before proceeding with HCT (AIII). Data are insufficient to recommend a drug prophylaxis regimen after HCT to prevent the recurrence of strongyloidiasis. HCT recipients who had strongyloidiasis before or after HCT should be monitored carefully for signs and symptoms of recurrent infection for at least 6 months after treatment (BIII).
Other recommendations
Unlike with allogeneic HCT, hyperinfection strongyloidiasis has been reported only rarely after autologous HCT; however, the same screening precautions should be used among autologous recipients (BIII). Indications for empirical treatment for strongyloidiasis before HCT are the same among children and adults, except for children weighing o15 kg, for whom the preferred drug is albendazole (BIII) (Appendix 1).
Recommendations regarding Trypanosoma cruzi and Leishmania
Preventing exposure T. cruzi, the etiological agent of Chagas disease, can be transmitted through blood transfusion.
518 Transfusionassociated transmission of T. cruzi is a well-known phenomenon in endemic countries, and seven instances have been reported in the United States and Canada, all in immunocompromised patients who had fulminant courses of acute Chagas disease. Serological screening of donated blood for T. cruzi in the United States began in January 2007, and although the Food And Drug Administration has not mandated screening, more than 70% of donated units are currently being screened. Sleeping sickness (T. brucei rhodesiense and T.b. gambiense) and leishmaniasis (various species belonging to the genus Leishmania) can also be transmitted through contaminated transfusions, although the possibility of leishmaniae or African trypanosomes causing problems in an HCT patient is extremely remote if the donor and recipient are from nonendemic areas. Reactivation of T. cruzi has been reported in HCT patients, but there are few reports of visceral leishmaniasis after HCT; 519-521 moreover, this case seemed to be acquired more than a year after transplantation and was not preexistent or transmitted by the stem cell product.
Donors or recipients who were born, received a blood transfusion or lived for at least 6 months in a Chagas disease endemic area (for example, parts of South and Central America and Mexico) should be screened serologically for anti-T. cruzi serum IgG Ab (BIII).
522 Similarly, a donor or recipient whose mother was born in a Chagas disease endemic area or who has an extensive maternal family history of cardiac disease (for example, cardiomegaly and dysrhythmias) should be screened because of the risk of congenital transmission (CIII). 518, 523 Persons who lived o6 months in a Chagas endemic area but who had high-risk living conditions (for example, having had extensive exposure to the Chagas disease vector-the reduviid bug-or having lived in dwellings with mud walls, unmilled logs and sticks, or with a thatched roof) should also be screened for evidence of T. cruzi infection (BIII).
In the absence of a gold standard test for Chagas disease, screening for infection should be performed with at least two serological tests (for example, enzyme immunoassay, indirect hemagglutination, indirect fluorescent Ab or radioimmunoprecipitation assay) (BIII). 524 Persons with active Chagas disease (DIII) or with a past history of Chagas disease (CIII) should not serve as HCT donors.
Preventing disease
Hematopoietic cell transplant candidates at risk for infection with T. cruzi should be screened for serum IgG anti-T. cruzi Ab (BIII).
522 T. cruzi seropositivity is not a contraindication to HCT. 522, 525 However, if an acute illness occurs in a T. cruzi-seropositive HCT recipient, particularly during neutropenia, T. cruzi reactivation should be included in the differential diagnosis (BIII).
525 Experts have proposed the use of benznidazole or nifurtimox for preemptive therapy or prophylaxis of recurrent T. cruzi among seropositive HCT recipients, 526 but insufficient data were found to make a recommendation. For additional information regarding the epidemiology of Chagas disease and for questions regarding evaluation and treatment, contact CDC/National Center for Zoonotic, Vector-borne and Enteric Diseases/Division of Parasitic Diseases (http:// www.cdc.gov/chagas, 770 488-7775, chagas@cdc.gov).
Other recommendations
Recommendations are the same for autologous or allogeneic recipients. However, recurrence of Chagas disease is probably less likely to occur among autologous recipients because of the shorter duration of immunosuppression. Recommendations are the same among children or adults.
Recommendations regarding malaria
In 2006, there were an estimated 247 million cases of malaria with more than 880 000 deaths. 527 Malaria is not an opportunistic disease, but it is increasingly relevant in SCT for several reasons:
More patients with either a history of malaria or residing in an endemic malaria region are being transplanted; more residents from endemic regions are being considered as donors; and more recipients are being exposed to malaria after transplant.
Preventing exposure
Preventing transmission through the stem cell product. Malaria, including falciparum malaria, has been transmitted by HCT even when donor smears before transplant are reportedly negative. [106] [107] [108] 528 All donors from endemic regions should be asked about a malaria history. Donors who have traveled to an area in which malaria transmission occurs should be deferred from donating for 1 year after their return. Former or current residents of an area in which malaria transmission occurs should be deferred for 3 years. If those deferral times are not feasible, the donor should receive empirical treatment for malaria before donating.
108 Blood smears, immunochromatogenic tests and PCR are all inappropriate tests for evaluating asymptomatic potential donors.
If the donor is diagnosed with an active infection, collection of the stem cell product should be delayed if possible until treatment has been completed and negative confirmatory testing obtained (AIII). If this is not feasible, preemptive treatment of the recipient seems reasonable, 106 but there is no evidence to make a recommendation.
Preventing mosquito bites. Hematopoietic cell transplant recipients who cannot avoid areas with malaria should try to avoid bites by Plasmodium-carrying mosquitoes. Anopheles mosquitoes are the most active at night. It is recommended that HCT recipients traveling to endemic malaria areas use insecticide-treated bed nets if they are to sleep in an open-air setting (AII). This practice has been shown to reduce severe malaria in children 529 and is recommended by the CDC and the World Health Organization for malaria control. Individual infection may be decreased by the use of long sleeves, long pants and mosquito repellents (AI) (for example, DEET (N,Ndiethyl-meta-toluamide, 30-50%)). The use of mosquito repellent seems to add to the protective effect of insecticidetreated bed nets.
530
Preventing disease HCT recipients from endemic areas or living in endemic areas. Hematopoietic cell transplant recipients from endemic areas should be screened by blood smears, rapid tests and/or PCR for active disease before transplantation (AIII). After HCT, patients should be screened if they develop fever, pancytopenia, hemophagocytosis syndrome, hepatosplenomegaly or other symptoms suggestive of malaria (AIII). However, reported occurrences of malaria in HCT recipients are rare, and evidence is insufficient to make specific recommendations for prophylaxis even in patients living in endemic areas. Involvement of a malarial specialist should be considered for additional management.
HCT recipients in nonendemic areas who are traveling to malaria endemic areas. Hematopoietic cell transplant recipients traveling to areas endemic for malaria should consult their physicians to choose an antimalarial regimen that is effective against the prevalent Plasmodium, which can be tolerated and is free of interactions with the patient's current medications (AIII). The CDC has a website with comprehensive information regarding travel (http:// wwwn.cdc.gov/travel/default.aspx).
